Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Surface Logix, a privately held biopharmaceutical company, has announced the appointment of Keith Dionne to the position of president and CEO and to its board of directors.
Subscribe to our email newsletter
Dr Dionne was previously CEO of Alantos Pharmaceuticals, where he led the company through the acquisition by Amgen for more than $300 million in cash. Prior to Alantos, Dr Dionne held senior-level positions at Millennium Pharmaceuticals, including most recently vice president of R&D strategy and vice president and general manager of technology business.
Steven Gillis, chairman of Surface Logix, said: “We are delighted to welcome Keith at this important stage of Surface Logix’s development. We are confident that his proven track record and depth of experience will be instrumental as the company continues to make progress on a number of fronts, including the further clinical development of two candidates in Phase II clinical trials.”